Faecal carriage of extended-spectrum β-lactamase-producing bacteria in the community

Eastern Mediterranean Health Journal

Volumn 15, Issue 6, 2009, Pages 1365-1370

  Kader, A A ^a   Kamath, K A ^a  

^a Almana General Hospital   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CARRIER; BACTERIUM DETECTION; CHILD; ESCHERICHIA COLI; FECES; FECES ANALYSIS; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; NONHUMAN; NORMAL HUMAN;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARRIER STATE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINASE; DISEASE RESERVOIRS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; HOSPITALS, GENERAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MASS SCREENING; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; SAUDI ARABIA;

EID: 75449100707     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clinical infectious diseases, 2003, 36:S11-23.
2. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Critical care medicine, 2001, 29:N75-81.
3. Bradford PA. Extended-spect rum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical microbiology reviews, 2001, 14:933-51.
4. Moland SE et al. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrobial agents and chemotherapy, 2002, 46:3837-42.
5. De Champs C et al. Prospective survey of colonization and infection caused by expanded-spectrum-β-lactamase-producing members of the family Entero-bacteriaceae in an intensive care unit. Journal of clinical microbiology, 1989, 27:2887-90.
6. Bou G et al. Identification and broad dissemination of the CTX-M-14 ß-lactamase in different Escherichia coli strains in the northwest area of Spain. Journal of clinical microbiology, 2002, 40:4030-6.
7. Hollander R et al. Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum β-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak. Journal of hospital infection, 2001, 48:207-13.
8. Bonomo RA et al. Cefotaxime-resistant bacteria colonizing older people admitted to an acute care hospital. Journal of the American Geriatric Society, 2003, 51:519-22.
9. Mirellis B et al. Community transmission of extended-spectrum β-lactamase. Emerging infectious diseases, 2003, 9:1024-5.
10. Rodríguez-Baño J et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalised patients. Journal of clinical microbiology, 2004, 42:1089-94.
11. Jutersek B et al. Complex endemic situation regarding extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a hospital in Slovenia. Microbiology and drug resistance, 2003, 9(Suppl.1):S25-33.
12. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Annals of Saudi medicine, 2005, 25 (3):239-42.
13. Performance standards for antimicrobial susceptibility testing: 15th informational supplement. Wayne, Pennsylvania, National Committee for Clinical Laboratory Standards, 2005 (M100-S15).
14. Cowan SF, Steel KJ. Manual for identification of medical bacteria, 3rd ed. Cambridge, Cambridge University Press, 1993.
15. Jarlier V et al. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of infectious diseases, 1988, 10:867-78.
16. Kader AA, Kumar A. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other Gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi medical journal, 2005, 26(6):956-9.
17. Woodford N et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. Journal of antimicrobial chemotherapy, 2004, 54:735-43.
18. Cormican M et al. Extended-spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community urinary tract infection. Diagnostic microbiology and infectious disease, 1998, 32:317-9.
19. Levin BR. Minimizing potential resistance: a population dynamics view. Clinical infectious diseases, 2001, 33(Suppl. 3):S161-9.
20. Livermore DM. Beta-lactamase-mediated resistance and opportunities for its control. Journal of antimicrobial agents, 1998, 41:25-41.
21. Bosi C et al. Most Enterobacter aerogenes strains in France belong to a prevalent clone. Journal of clinical microbiology, 1999, 37:2165-9.
22. Bonten MJ et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Archives internal medicine, 1998, 158:1127-32.
23. Colodner R et al. Risk factors for the development of extended-spectrum β-lactamase producing bacteria in non-hospitalized patients. European journal of clinical microbiology and infectious diseases, 2004, 23:163-7.
24. Heseltine P. Has resistance spread to the community? Clinical microbiology and infection, 2000, 6:11-6.
25. Lucet JC et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit epidemiology and risk factors for acquisition. Clinical infectious diseases, 1996, 22:430-6.